Universal Beteiligungs und Servicegesellschaft mbH Trims Stock Holdings in United Therapeutics Corporation $UTHR

Universal Beteiligungs und Servicegesellschaft mbH lessened its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 10.6% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 39,075 shares of the biotechnology company’s stock after selling 4,619 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in United Therapeutics were worth $16,381,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. F m Investments LLC lifted its holdings in shares of United Therapeutics by 1.3% in the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after acquiring an additional 33 shares during the last quarter. HB Wealth Management LLC raised its position in United Therapeutics by 2.9% in the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 35 shares during the period. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Park Avenue Securities LLC lifted its stake in United Therapeutics by 1.7% during the second quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock worth $676,000 after purchasing an additional 39 shares in the last quarter. Finally, Coldstream Capital Management Inc. boosted its position in shares of United Therapeutics by 2.0% during the second quarter. Coldstream Capital Management Inc. now owns 2,145 shares of the biotechnology company’s stock worth $616,000 after buying an additional 43 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Trading Down 0.7%

Shares of NASDAQ:UTHR opened at $468.94 on Friday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $519.99. The company’s 50 day moving average is $487.66 and its two-hundred day moving average is $414.12. The company has a market cap of $20.19 billion, a PE ratio of 17.77, a P/E/G ratio of 2.53 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company’s revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.39 earnings per share. As a group, equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Activity

In other news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $429.25, for a total value of $9,658,125.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 563,364 shares of company stock worth $266,247,272. Corporate insiders own 10.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Royal Bank Of Canada boosted their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. HC Wainwright boosted their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.